Mischa Houtkamp Selected Research

Disease Progression

2/2014

An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mischa Houtkamp Research Topics

Disease

6	Neoplasms (Cancer) 01/2021 - 10/2004
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Disease Progression 02/2014
1	Inflammation (Inflammations) 01/2012
1	Exanthema (Rash) 01/2012

Drug/Important Bio-Agent (IBA)

3	ErbB Receptors (EGF Receptor)IBA 01/2012 - 10/2004
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 02/2014
2	zalutumumabIBA 05/2014 - 01/2012
2	Monoclonal AntibodiesIBA 01/2012 - 10/2004
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	AntibodiesIBA 05/2014
1	auristatinIBA 02/2014
1	Antineoplastic Agents (Antineoplastics)IBA 02/2014
1	Thromboplastin (Tissue Factor)IBA 02/2014
1	Factor VIIa (Activated Factor VII)IBA 02/2014
1	Interleukin-8 (Interleukin 8)IBA 01/2012
1	LigandsIBA 08/2006
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2004
1	Indicators and Reagents (Reagents)IBA 10/2004
1	Epidermal Growth Factor (EGF)IBA 10/2004

Therapy/Procedure

4	Therapeutics 01/2021 - 10/2004
1	Immunotherapy 01/2021
1	Subcutaneous Injections 01/2012